Adaptive Biotechnologies Corporation Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/8/2026)
| Balance Sheet | Total Assets | 512,736,000.00 | ROE | 42.67 % |
| Balance Sheet | Total Equity | 218,793,000.00 | ROA | -11.60 % |
| Cashflow | Capital Expenditures | -2,959,000.00 | P/FCF | -79.42 |
| Cashflow | Free Cash Flow | -48,945,000.00 | – | – |
| Cashflow | Operating Cash Flow | -45,986,000.00 | P/CF | -84.53 |
| Income | Earnings per Share (diluted) | -0.39 | Div. Yield | – |
| Income | Net Income | -59,499,000.00 | P/E | -65.69 |
| Income | Shares Outstanding | 151,722,000.00 | P/B | 17.77 |
| Income | Total Revenue | 276,976,000.00 | P/S | 14.03 |
Ratios calculated on: 10/14/2026
Company Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.adaptivebiotech.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more